000849954 001__ 849954
000849954 005__ 20210129234354.0
000849954 0247_ $$2doi$$a10.1212/WNL.0000000000005956
000849954 0247_ $$2ISSN$$a0028-3878
000849954 0247_ $$2ISSN$$a1526-632X
000849954 0247_ $$2pmid$$apmid:29970404
000849954 0247_ $$2WOS$$aWOS:000442266600006
000849954 0247_ $$2altmetric$$aaltmetric:44532212
000849954 037__ $$aFZJ-2018-04049
000849954 082__ $$a610
000849954 1001_ $$0P:(DE-Juel1)131613$$aBarbe, Michael$$b0$$eCorresponding author
000849954 245__ $$aDBS of the PSA and the VIM in essential tremor
000849954 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2018
000849954 3367_ $$2DRIVER$$aarticle
000849954 3367_ $$2DataCite$$aOutput Types/Journal article
000849954 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1547048931_3110
000849954 3367_ $$2BibTeX$$aARTICLE
000849954 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000849954 3367_ $$00$$2EndNote$$aJournal Article
000849954 520__ $$aObjective To evaluate deep brain stimulation (DBS) of the posterior subthalamic area (PSA) in essential tremor (ET) and compare it to the ventral intermediate nucleus of the thalamus (VIM) in terms of stimulation efficacy, efficiency, and side effects.Methods DBS leads were implanted such that contacts were placed in the VIM, on the intercommissural line, and in the PSA. Thirteen patients with ET entered a randomized, double-blind crossover phase and completed a 1-year follow-up.Results PSA-DBS significantly reduced tremor severity and improved quality of life. There were no relevant differences in quality and frequency of stimulation side effects between VIM and PSA, with a tendency toward greater tremor improvement with PSA stimulation. Clinical benefit was achieved at significantly lower stimulation amplitudes in the PSA. The majority of patients remained with PSA-DBS after 1 year.Conclusion In accordance with previous retrospective investigations, our prospective data suggest that PSA-DBS is at least equally effective as but possibly more efficient than VIM-DBS.Classification of evidence This study provides Class I evidence that for patients with essential tremor, PSA-DBS is not significantly different from VIM-DBS in suppressing tremor, but clinical benefit from PSA-DBS is attained at lower stimulation amplitudes.
000849954 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000849954 588__ $$aDataset connected to CrossRef
000849954 7001_ $$0P:(DE-HGF)0$$aReker, Paul$$b1
000849954 7001_ $$0P:(DE-HGF)0$$aHamacher, Stefanie$$b2
000849954 7001_ $$0P:(DE-HGF)0$$aFranklin, Jeremy$$b3
000849954 7001_ $$0P:(DE-HGF)0$$aKraus, Daria$$b4
000849954 7001_ $$0P:(DE-HGF)0$$aDembek, Till A.$$b5
000849954 7001_ $$0P:(DE-HGF)0$$aBecker, Johannes$$b6
000849954 7001_ $$0P:(DE-HGF)0$$aSteffen, Julia K.$$b7
000849954 7001_ $$0P:(DE-HGF)0$$aAllert, Niels$$b8
000849954 7001_ $$0P:(DE-HGF)0$$aWirths, Jochen$$b9
000849954 7001_ $$0P:(DE-HGF)0$$aDafsari, Haidar S.$$b10
000849954 7001_ $$0P:(DE-HGF)0$$aVoges, Jürgen$$b11
000849954 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b12
000849954 7001_ $$0P:(DE-HGF)0$$aVisser-Vandewalle, Veerle$$b13
000849954 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b14
000849954 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000005956$$gp. 10.1212/WNL.0000000000005956 -$$n6$$ppage 247$$tNeurology$$v91$$x1526-632X$$y2018
000849954 909CO $$ooai:juser.fz-juelich.de:849954$$pVDB
000849954 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131613$$aForschungszentrum Jülich$$b0$$kFZJ
000849954 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b12$$kFZJ
000849954 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000849954 9141_ $$y2018
000849954 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000849954 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2015
000849954 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000849954 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000849954 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000849954 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000849954 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000849954 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000849954 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000849954 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000849954 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000849954 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000849954 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2015
000849954 920__ $$lyes
000849954 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000849954 980__ $$ajournal
000849954 980__ $$aVDB
000849954 980__ $$aI:(DE-Juel1)INM-3-20090406
000849954 980__ $$aUNRESTRICTED